|
rdf:type |
|
|
lifeskim:mentions |
|
|
pubmed:issue |
23
|
|
pubmed:dateCreated |
2007-6-7
|
|
pubmed:databankReference |
|
|
pubmed:abstractText |
Amyloid A (AA) amyloidosis is a complication of chronic inflammatory conditions that develops when proteolytic fragments of serum amyloid A protein (SAA) are deposited in tissues as amyloid fibrils. Amyloid deposition in the kidney causes progressive deterioration in renal function. Eprodisate is a member of a new class of compounds designed to interfere with interactions between amyloidogenic proteins and glycosaminoglycans and thereby inhibit polymerization of amyloid fibrils and deposition of the fibrils in tissues.
|
|
pubmed:grant |
|
|
pubmed:commentsCorrections |
|
|
pubmed:language |
eng
|
|
pubmed:journal |
|
|
pubmed:citationSubset |
AIM
|
|
pubmed:chemical |
|
|
pubmed:status |
MEDLINE
|
|
pubmed:month |
Jun
|
|
pubmed:issn |
1533-4406
|
|
pubmed:author |
pubmed-author:BalshawRobertR,
pubmed-author:ButrimieneIrenaI,
pubmed-author:DemberLaura MLM,
pubmed-author:Eprodisate for AA Amyloidosis Trial Group,
pubmed-author:GarceauDenisD,
pubmed-author:GorevicPeter DPD,
pubmed-author:HauckWendyW,
pubmed-author:HawkinsPhilip NPN,
pubmed-author:HazenbergBouke P CBP,
pubmed-author:LachmannHelen JHJ,
pubmed-author:LesnyakOlgaO,
pubmed-author:LivnehAviA,
pubmed-author:MerliniGiampaoloG,
pubmed-author:ObiciLauraL,
pubmed-author:PuéchalXavierX,
pubmed-author:SkinnerMarthaM
|
|
pubmed:copyrightInfo |
Copyright 2007 Massachusetts Medical Society.
|
|
pubmed:issnType |
Electronic
|
|
pubmed:day |
7
|
|
pubmed:volume |
356
|
|
pubmed:owner |
NLM
|
|
pubmed:authorsComplete |
Y
|
|
pubmed:pagination |
2349-60
|
|
pubmed:dateRevised |
2010-11-18
|
|
pubmed:meshHeading |
pubmed-meshheading:17554116-Amyloidosis,
pubmed-meshheading:17554116-Arthritis, Rheumatoid,
pubmed-meshheading:17554116-Creatinine,
pubmed-meshheading:17554116-Disease Progression,
pubmed-meshheading:17554116-Double-Blind Method,
pubmed-meshheading:17554116-Familial Mediterranean Fever,
pubmed-meshheading:17554116-Female,
pubmed-meshheading:17554116-Glycosaminoglycans,
pubmed-meshheading:17554116-Humans,
pubmed-meshheading:17554116-Kaplan-Meier Estimate,
pubmed-meshheading:17554116-Kidney Diseases,
pubmed-meshheading:17554116-Kidney Failure, Chronic,
pubmed-meshheading:17554116-Male,
pubmed-meshheading:17554116-Middle Aged,
pubmed-meshheading:17554116-Propane,
pubmed-meshheading:17554116-Proportional Hazards Models,
pubmed-meshheading:17554116-Proteinuria,
pubmed-meshheading:17554116-Serum Amyloid A Protein,
pubmed-meshheading:17554116-Sulfonic Acids
|
|
pubmed:year |
2007
|
|
pubmed:articleTitle |
Eprodisate for the treatment of renal disease in AA amyloidosis.
|
|
pubmed:affiliation |
Boston University School of Medicine, Boston, MA 02118, USA. ldember@bu.edu
|
|
pubmed:publicationType |
Journal Article,
Research Support, U.S. Gov't, P.H.S.,
Randomized Controlled Trial,
Research Support, Non-U.S. Gov't,
Multicenter Study
|
